Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Recruiting now · Phase 1/Phase 2

Conditions studied: Non-Small-Cell Lung Cancer

In brief

Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC

Key facts

Study ID

NCT06343064

Run by

Avistone Biotechnology Co., Ltd.

People needed

156

Starts

2023-06-13

Expected to finish

2026-12-31

Last updated by the study team

2025-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and willingness to sign a written informed consent document.
• Aged at least 18 years old.
• Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV).
• EGFR mutations, including exon 19 deletion and exon 21 L858R.
• C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI.
• At least one measurable lesion as defined by RECIST V1.1.
• ECOG performance status 0 to 1.

You may not qualify if…

• Previous treatment with MET inhibitors or HGF-targeted therapy.
• There are mutations of ALK or ROS1.
• Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
• Pregnant or nursing women.

Where it is running

• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.